OTCMKTS:EFTR

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

eFFECTOR Therapeutics logo
$0.0002 0.00 (-75.00%)
As of 11:10 AM Eastern

About eFFECTOR Therapeutics Stock (OTCMKTS:EFTR)

Advanced

Key Stats

Today's Range
$0.0002
▼
$0.0002
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.02
Volume
3,500 shs
Average Volume
5,694 shs
Market Capitalization
$940.80
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment.

The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). These programs have been studied as potential treatments for solid tumors and other cancers, both as standalone therapies and in combination with existing treatments.

Founded in 2012 and headquartered in San Diego, California, eFFECTOR has operated primarily as a research and development company serving the oncology biopharmaceutical market. The company was led by co-founder Steven A. Worland, who has served as president and chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review.

AI Generated. May Contain Errors.

eFFECTOR Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
0th Percentile Overall Score

EFTR MarketRank™: 
0.017250530785 of 5 stars

eFFECTOR Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for eFFECTOR Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about eFFECTOR Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the float of eFFECTOR Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    eFFECTOR Therapeutics has a short interest ratio ("days to cover") of 32.34, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    eFFECTOR Therapeutics does not currently pay a dividend.

  • Dividend Growth

    eFFECTOR Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for eFFECTOR Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.70% of the stock of eFFECTOR Therapeutics is held by insiders.

  • Percentage Held by Institutions

    57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about eFFECTOR Therapeutics' insider trading history.
Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EFTR Stock News Headlines

eFFECTOR Therapeutics (EFTR) Set to Release Quarterly Earnings on Tuesday
EFTR - eFFECTOR Therapeutics, Inc.
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Headlines

EFTR Stock Analysis - Frequently Asked Questions

eFFECTOR Therapeutics' stock was trading at $0.0002 at the start of the year. Since then, EFTR stock has increased by 0.0% and is now trading at $0.0002.

eFFECTOR Therapeutics, Inc. (OTCMKTS:EFTR) issued its quarterly earnings results on Monday, November, 8th. The company reported $10.50 EPS for the quarter, topping analysts' consensus estimates of ($6.50) by $17.00. The business had revenue of $430 thousand for the quarter.

eFFECTOR Therapeutics's stock reverse split before market open on Friday, January 12th 2024.The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Snap (SNAP), CrowdStrike (CRWD), Netflix (NFLX), NVIDIA (NVDA) and PayPal (PYPL).

Company Calendar

Today
11/17/2026
Next Earnings (Estimated)
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:EFTR
Previous Symbol
NASDAQ:EFTR
CIK
1828522
Fax
N/A
Employees
10
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,704,000
Free Float
4,483,000
Market Cap
$940.80
Optionable
No Data
Beta
2.91

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (OTCMKTS:EFTR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners